Boston Scientific just received approval from the EU to market the company’s newest family of pacemakers.
The following features are listed in the press release:
ALTRUA is Boston Scientific’s most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly — usually less than 60 beats per minute — depriving the body of sufficient oxygen.
Multiple Atrial Ventricular (AV) Delay programming options: These options are designed to reduce unnecessary right ventricular (RV) pacing, without dropping ventricular beats, a key distinction from other competitive RV pacing algorithms. The ALTRUA 50 and 60 series also include an enhanced AV search hysteresis feature, now with an extendable AV delay out to 400 milliseconds, providing physicians with additional flexibility to tailor device programming for unique patient needs. Minute Ventilation (MV) Blended Sensor: This proprietary technology treats a condition called Chronotropic Incompetence, which is the inability of the heart to regulate its rate appropriately in response to physical activity and emotional stress. Boston Scientific’s MV Blended sensor is the only sensor that has been shown to restore Chronotropic Competence. Ventricular Rate Regulation (VRR): This feature helps physicians manage patients with frequent atrial arrythmias. Automatic Capture: This capability is designed to offer automatic, safe and accurate ventricular pulse management. The device checks every heart beat to see if the lower chambers of the heart contract in response to the delivered pulse. If no contraction is detected, a backup pace with more energy is delivered.